Transitioning to composite bacterial mutagenicity models in ICH M7 (Q)SAR analyses.

The International Council on Harmonisation (ICH) M7(R1) guideline describes the use of complementary (quantitative) structure-activity relationship ((Q)SAR) models to assess the mutagenic potential of drug impurities in new and generic drugs. Historically, the CASE Ultra and Leadscope software platforms used two different statistical-based models to predict mutations at G-C (guanine-cytosine) and A-T (adenine-thymine) sites, to comprehensively assess bacterial mutagenesis. In the present study, composite bacterial mutagenicity models covering multiple mutation types were developed. These new models contain more than double the number of chemicals (n = 9254 and n = 13,514) than the corresponding non-composite models and show better toxicophore coverage. Additionally, the use of a single composite bacterial mutagenicity model simplifies impurity analysis in an ICH M7 (Q)SAR workflow by reducing the number of model outputs requiring review. An external validation set of 388 drug impurities representing proprietary pharmaceutical chemical space showed performance statistics ranging from of 66-82% in sensitivity, 91-95% in negative predictivity and 96% in coverage. This effort represents a major enhancement to these (Q)SAR models and their use under ICH M7(R1), leading to improved patient safety through greater predictive accuracy, applicability, and efficiency when assessing the bacterial mutagenic potential of drug impurities.

[1]  Nigel Greene,et al.  It's difficult, but important, to make negative predictions. , 2016, Regulatory toxicology and pharmacology : RTP.

[2]  Heather Scott,et al.  Ames positive boronic acids are not all eukaryotic genotoxins. , 2015, Mutation research. Genetic toxicology and environmental mutagenesis.

[3]  Roustem D Saiakhov,et al.  Computing similarity between structural environments of mutagenicity alerts , 2019, Mutagenesis.

[4]  D. Strauss,et al.  Translating New Science Into the Drug Review Process: The US FDA's Division of Applied Regulatory Science. , 2018 .

[5]  E. Zeiger,et al.  Salmonella mutagenicity tests: III. Results from the testing of 255 chemicals. , 1987, Environmental mutagenesis.

[6]  Glenn J. Myatt,et al.  LeadScope: Software for Exploring Large Sets of Screening Data , 2000, J. Chem. Inf. Comput. Sci..

[7]  Scott Boyer,et al.  Use of in silico systems and expert knowledge for structure-based assessment of potentially mutagenic impurities. , 2013, Regulatory toxicology and pharmacology : RTP.

[8]  M T D Cronin,et al.  A review of the electrophilic reaction chemistry involved in covalent DNA binding , 2010, Critical reviews in toxicology.

[9]  Neal F. Cariello,et al.  Comparison of the computer programs DEREK and TOPKAT to predict bacterial mutagenicity. Deductive Estimate of Risk from Existing Knowledge. Toxicity Prediction by Komputer Assisted Technology. , 2002, Mutagenesis.

[10]  Gilles Klopman,et al.  Optimizing Predictive Performance of CASE Ultra Expert System Models Using the Applicability Domains of Individual Toxicity Alerts , 2012, J. Chem. Inf. Model..

[11]  Luis G Valerio,et al.  Characterization and validation of an in silico toxicology model to predict the mutagenic potential of drug impurities. , 2012, Toxicology and applied pharmacology.

[12]  N. Kruhlak,et al.  An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: II. Identification of genotoxicants, reprotoxicants, and carcinogens using in silico methods. , 2006, Regulatory toxicology and pharmacology : RTP.

[13]  Craig Zwickl,et al.  An evaluation of in-house and off-the-shelf in silico models: implications on guidance for mutagenicity assessment. , 2015, Regulatory toxicology and pharmacology : RTP.

[14]  Lemont B. Kier,et al.  New predictors for several ADME/Tox properties: Aqueous solubility, human oral absorption, and Ames genotoxicity using topological descriptors , 2004, Molecular Diversity.

[15]  E. Zeiger,et al.  The Ames Salmonella/microsome mutagenicity assay. , 2000, Mutation research.

[16]  J. Kazius,et al.  Derivation and validation of toxicophores for mutagenicity prediction. , 2005, Journal of medicinal chemistry.

[17]  Gilles Klopman,et al.  Effectiveness of CASE Ultra Expert System in Evaluating Adverse Effects of Drugs , 2013, Molecular informatics.

[18]  Samuel J. Webb,et al.  Self organising hypothesis networks: a new approach for representing and structuring SAR knowledge , 2014, Journal of Cheminformatics.

[19]  Romualdo Benigni,et al.  Mechanisms of chemical carcinogenicity and mutagenicity: a review with implications for predictive toxicology. , 2011, Chemical reviews.

[20]  Tudor I. Oprea,et al.  In silico toxicology protocols. , 2018, Regulatory toxicology and pharmacology : RTP.

[21]  R. Saracci,et al.  Describing the validity of carcinogen screening tests. , 1979, British Journal of Cancer.

[22]  Errol Zeiger,et al.  Measuring Intra-Assay Agreement for the Ames Salmonella Assay , 1991 .

[23]  Matthew D Segall,et al.  Addressing toxicity risk when designing and selecting compounds in early drug discovery. , 2014, Drug discovery today.

[24]  Nigel Greene,et al.  Evaluation of a statistics-based Ames mutagenicity QSAR model and interpretation of the results obtained. , 2016, Regulatory toxicology and pharmacology : RTP.

[25]  GUIDANCE DOCUMENT,et al.  Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use , 2008 .

[26]  E. Zeiger,et al.  Salmonella mutagenicity test results for 250 chemicals. , 1983, Environmental mutagenesis.

[27]  F. Guengerich,et al.  Mechanisms of formation of DNA adducts from ethylene dihalides, vinyl halides, and arylamines. , 1994, Drug metabolism reviews.

[28]  Lidiya Stavitskaya,et al.  Extending (Q)SARs to incorporate proprietary knowledge for regulatory purposes: A case study using aromatic amine mutagenicity. , 2016, Regulatory toxicology and pharmacology : RTP.

[29]  Krista Dobo,et al.  Determination of compound-specific acceptable daily intakes for 11 mutagenic carcinogens used in pharmaceutical synthesis. , 2013, Regulatory toxicology and pharmacology : RTP.

[30]  E. Zeiger,et al.  Salmonella mutagenicity tests: IV. Results from the testing of 300 chemicals , 1988, Environmental and molecular mutagenesis.

[31]  Lidiya Stavitskaya,et al.  Principles and procedures for implementation of ICH M7 recommended (Q)SAR analyses. , 2016, Regulatory toxicology and pharmacology : RTP.

[32]  Lidiya Stavitskaya,et al.  Principles and procedures for handling out-of-domain and indeterminate results as part of ICH M7 recommended (Q)SAR analyses , 2018, Regulatory toxicology and pharmacology : RTP.

[33]  Lutz Müller,et al.  Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. , 2005, Mutation research.

[34]  Lutz Müller,et al.  A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity. , 2006, Regulatory toxicology and pharmacology : RTP.

[35]  Andrew Teasdale,et al.  ICH M7: Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk , 2017 .

[36]  A. Giuliani,et al.  Computer-assisted analysis of interlaboratory Ames test variability. , 1988, Journal of toxicology and environmental health.

[37]  Alessandro Giuliani,et al.  Improvement of quantitative structure–activity relationship (QSAR) tools for predicting Ames mutagenicity: outcomes of the Ames/QSAR International Challenge Project , 2018, Mutagenesis.

[38]  D. Gatehouse,et al.  Bacterial mutagenicity assays: test methods. , 2012, Methods in molecular biology.

[39]  Mark W Powley,et al.  (Q)SAR assessments of potentially mutagenic impurities: a regulatory perspective on the utility of expert knowledge and data submission. , 2015, Regulatory toxicology and pharmacology : RTP.

[40]  Nigel Greene,et al.  A practical application of two in silico systems for identification of potentially mutagenic impurities. , 2015, Regulatory toxicology and pharmacology : RTP.

[41]  Lidiya Stavitskaya,et al.  Establishing best practise in the application of expert review of mutagenicity under ICH M7. , 2015, Regulatory toxicology and pharmacology : RTP.

[42]  E. Zeiger,et al.  Salmonella mutagenicity tests: II. Results from the testing of 270 chemicals. , 1986, Environmental mutagenesis.

[43]  J. Ashby,et al.  Prediction of Salmonella mutagenicity. , 1996, Mutagenesis.

[44]  Jun Li,et al.  In silico and in vitro genotoxicity evaluation of descarboxyl levofloxacin, an impurity in levofloxacin , 2014, Drug and chemical toxicology.

[45]  H. Seifried,et al.  A compilation of two decades of mutagenicity test results with the Ames Salmonella typhimurium and L5178Y mouse lymphoma cell mutation assays. , 2006, Chemical research in toxicology.

[46]  B A Bridges,et al.  Use of a simplified fluctuation test to detect low levels of mutagens. , 1976, Mutation research.

[47]  B. Ames,et al.  Revised methods for the Salmonella mutagenicity test. , 1983, Mutation research.

[48]  R. Tennant,et al.  Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP. , 1991, Mutation research.

[49]  Klaus-Robert Müller,et al.  Benchmark Data Set for in Silico Prediction of Ames Mutagenicity , 2009, J. Chem. Inf. Model..

[50]  B. Ames,et al.  An improved bacterial test system for the detection and classification of mutagens and carcinogens. , 1973, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Lidiya Stavitskaya,et al.  Construction and application of (Q)SAR models to predict chemical‐induced in vitro chromosome aberrations , 2018, Regulatory toxicology and pharmacology : RTP.

[52]  Lidiya Stavitskaya,et al.  Chemical Structure-Based and Toxicogenomic Models , 2015 .

[53]  Carol A Marchant,et al.  In Silico Tools for Sharing Data and Knowledge on Toxicity and Metabolism: Derek for Windows, Meteor, and Vitic , 2008, Toxicology mechanisms and methods.

[54]  R D Benz,et al.  (Q)SAR Modeling and Safety Assessment in Regulatory Review , 2012, Clinical pharmacology and therapeutics.

[55]  J. Ashby.  Fundamental structural alerts to potential carcinogenicity or noncarcinogenicity. , 1985, Environmental mutagenesis.

[56]  Glenn J. Myatt,et al.  CHAPTER 9:In silico Toxicology: An Overview of Toxicity Databases, Prediction Methodologies, and Expert Review , 2017 .

[57]  Lidiya Stavitskaya,et al.  Ensuring Regulatory Acceptable (Q)SAR Models and Expert Alerts for ICH M7 Reflect Proprietary Chemical Space , 2014 .

[58]  N. Kruhlak,et al.  In silico screening of chemicals for bacterial mutagenicity using electrotopological E-state indices and MDL QSAR software. , 2005, Regulatory toxicology and pharmacology : RTP.

[59]  N. Kruhlak,et al.  An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: I. Identification of carcinogens using surrogate endpoints. , 2006, Regulatory toxicology and pharmacology : RTP.

[60]  R. Tennant,et al.  Chemical structure, Salmonella mutagenicity and extent of carcinogenicity as indicators of genotoxic carcinogenesis among 222 chemicals tested in rodents by the U.S. NCI/NTP. , 1988, Mutation research.

[61]  Susanne Glowienke,et al.  Mutagenicity assessment strategy for pharmaceutical intermediates to aid limit setting for occupational exposure. , 2015, Regulatory toxicology and pharmacology : RTP.

[62]  Alexander Amberg,et al.  Do Carboxylic/Sulfonic Acid Halides Really Present a Mutagenic and Carcinogenic Risk as Impurities in Final Drug Products? , 2015 .